Five Prime therapeutics Inc. (NASDAQ:FPRX) has announced it has entered into a collaboration agreement with Bristol Myers Squibb Co (NYSE:BMY) for the discovery and development of immune-oncology therapies. Five Prime Therapeutics Inc (NASDAQ:FPRX) stock performance was 22.61% in last session and finished the day at $22.99. Traded volume was 1,287,393 million shares in the last session and the average volume of the stock remained 120.37 million shares. Five Prime Therapeutics Inc (NASDAQ:FPRX) insider ownership is 2.30%.

Albany Molecular Research, Inc. (NASDAQ:AMRI) is expected to invest about $250 million in its Buffalo operations where it hopes to handle a major pharmaceutical contract that it has secured. Had it not been for the delays, the project would have been up and running by February, at least in small-scale level. Albany Molecular Research, Inc. (NASDAQ:AMRI) rose 0.16 percent to $18.84 yesterday on volume of 1.02 million shares. The intra-day range of the stock was $17.87 to $19.07. Albany Molecular Research, Inc. (NASDAQ:AMRI) has a market capitalization of $595.30 million.

Vanda Pharmaceuticals (NASDAQ:VNDA) Director Thomas Watkins sold 35,000 shares of the stock on the open market in a transaction dated Friday, March 14th. The stock was sold at an average price of $17.66, for a total transaction of $618,100.00.Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)’s stock on Mar17, 2014 reported an increase of 2.15% to the closing price of $18.03. Its fifty two weeks range is $3.75 -$18.48. The total market capitalization recorded $604.04 million. The overall volume in the last trading session was 643,717 million shares. In its share capital, Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has 33.28 million outstanding shares.

Chimerix Inc. (NASDAQ:CMRX) has been entered into an agreement with the Food and Drug Administration. The agreement comes at the back of intensified lobbying and plead from the general public for the company to allow doctors use one of its pill to save Josh, a 9 month old boy suffering from a rare form of Kidney cancer. On Monday, shares of Chimerix Inc (NASDAQ:CMRX) dropped -3.98% to close the day at $26.06. Company return on investment (ROI) is 3.20% and its monthly performance is recorded as 33.37%. Chimerix Inc (NASDAQ:CMRX) quarterly revenue growth is 84.30%.